Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases

Journal of Invertebrate Pathology

Volumn 107, Issue SUPPL., 2011, Pages

  Galibert, Lionel ^a   Merten, Otto Wilhelm ^a  

^a GÉNÉTHON   (France)

Author keywords

AAV; Baculovirus expression system; Gene therapy; Large scale vector production; Neuromuscular diseases

Indexed keywords

ADENO ASSOCIATED VIRUS; ANIMAL; ARMYWORM; BACULOVIRUS; BIOTECHNOLOGY; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; NEUROMUSCULAR DISEASE; REVIEW; VIROLOGY;

ANIMALS; BACULOVIRIDAE; BIOTECHNOLOGY; DEPENDOVIRUS; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEUROMUSCULAR DISEASES; SPODOPTERA;

ADENO-ASSOCIATED VIRUS; HEXAPODA; MAMMALIA;

EID: 79960619313     PISSN: 00222011     EISSN: 10960805     Source Type: Journal    
DOI: 10.1016/j.jip.2011.05.008     Document Type: Review

References (160)

1. Allen J.M., Debelak D.J., Reynolds T.C., Miller A.D. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J. Virol. 1997, 71:6816-6822.
2. Aartsma-Rus A., Fokkema I., Verschuuren J., Ginjaar I., van Deutekom J., van Ommen G.J., den Dunnen J.T. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 2009, 30:293-299.
3. Aslanidi G., Lamb K., Zolotukhin S. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc. Natl. Acad. Sci. USA 2009, 106:5059-5064.
4. Aucoin M.G., Mena J.A., Kamen A.A. Bioprocessing of baculoviurs virus: a review. Curr. Gene Ther. 2010, 10:174-186.
5. Aucoin M.G., Perrier M., Kamen A.A. Improving AAV vector yield in insect cells by modulating the temperature after infection. Biotechnol. Bioeng. 2007, 97:1501-1509.
6. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., Viswanathan A., Holder G.E., Stockman A., Tyler N., Petersen-Jones S., Bhattacharya S.S., Thrasher A.J., Fitzke F.W., Carter B.J., Rubin G.S., Moore A.T., Ali R.R. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2231-2239.
7. Bédard C., Perret S., Kamen A.A. Fed-batch cultures of Sf-9 cells supports 3 x 107 cells per ml and improves baculovirus-expressed recombinant protein yields. Biotechnol. Lett. 1997, 19:629-632.
8. Berns K.I. Parvoviridae: the virus and their replication. Fields in Virology 1995, 2173-2197. Lippincott - Raven, Philadelphia. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
9. Bhatia R., Jesionowski G., Ferrance J., Ataai M.M. Insect cell physiology. Cytotechnology 1997, 24:1-9.
10. Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 2002, 82:291-329.
11. Bleker S., Sonntag F., Kleinschmidt J.A. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 2005, 79:2528-2540.
12. Blouin V., Brument N., Toublanc E., Raimbaud I., Moullier P., Salvetti A. Improving rAAV production and purification: towards the definition of a scaleable process. J. Gene Med. 2004, 6(Suppl 1):S223-228.
13. Booth M.J., Mistry A., Li X., Thrasher A., Coffin R.S. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther. 2004, 11:829-837.
14. Boutin S., Monteilhet V., Veron P., Leborgne C., Benveniste O., Montus M.F., Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 2010, 21:704-712.
15. Brown C.S., Welling-Wester S., Feijlbrief M., Van Lent J.W., Spaan W.J. Chimeric parvovirus B19 capsids for the presentation of foreign epitopes. Virology 1994, 198:477-488.
16. Brown, P., Barrett, S., Godwin, S., Trudinger, M., Marschak, T., Norboe, D., McQuiston, S., Kurtzman, G., 1998. Optimization of Production of Adeno-associated Virus (AAV) for use in Gene Therapy. Presented at: Cell Culture Engineering VI, San Diego/CA.
17. Casal J.L. Parvovirus diagnostics and vaccine production in insect cells. Cytotechnology 1996, 10:261-270.
18. Casal J.I. Use of the baculovirus expression system for the generation of virus-like particles. Biotechnol. Genet. Eng. Rev. 2001, 18:73-87.
19. Cecchini, S., Virag, T., Kotin, R., 2011. Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02 to 200 liter cultures. Hum. Gene Ther. 2011, doi:10.1089/hum.2010.250.
20. Chadeuf G., Favre D., Tessier J., Provost N., Nony P., Kleinschmidt J., Moullier P., Salvetti A. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med. 2000, 2:260-268.
21. Chang L.-S., Shi Y., Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J. Virol. 1989, 63:3479-3488.
22. Chen H. Intron splicing-mediated expression of AAV rep and cap genes and production of AAV vectors in insect cells. Mol. Ther. 2008, 16:924-930.
23. Chiorini J.A., Kim F., Yang L., Kotin R.M. Cloning and characterization of adeno-associated virus type 5. J. Virol. 1999, 73:1309-1319.
24. Chiorini J.A., Yang L., Liu Y., Safer B., Kotin R.M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 1997, 71:6823-6833.
25. Clark K.R., Voulgaropoulou F., Johnson P.R. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 1996, 3:1124-1132.
26. Collaco R.F., Cao X., Trempe J.P. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999, 238:397-405.
27. Condreay J.P., Kost T.A. Baculovirus expression vectors for insect and mammalian cells. Curr. Drug Targets 2007, 8:1126-1131.
28. Conway J., Rhys C.M., Zolotukhin I., Zolotukhin S., Muzyczka N., Hayward G.S., Byrne B.J. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther. 1999, 6:986-993.
29. Conway J.E., Zolotukhin S., Muzyczka N., Hayward G.S., Byrne B.J. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 1997, 71:8780-8789.
30. Cox M.M.J., Anderson D.K. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respi Viruses 2007, 1:35-40.
31. Denti M.A., Rosa A., D'Antona G., Sthandier O., De Angelis F.G., Nicoletti C., Allocca M., Pansarasa O., Parente V., Musarò A., Auricchio A., Bottinelli R., Bozzoni I. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. USA 2006, 103:3758-3763.
32. Dezawa M., Ishikawa H., Itokazu Y., Yoshihara T., Hoshino M., Takeda S., Ide C., Nabeshima Y. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005, 309:314-317.
33. Duan D., Sharma P., Yang J., Yue Y., Dudus L., Zhang Y., Fisher K.J., Engelhardt J.F. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 1998, 72:8568-8577.
34. Durocher Y., Pham P.L., St-Laurent G., Jacob D., Cass B., Chahal P., Lau C.J., Nalbantoglu J., Kamen A. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J. Virol. Methods 2007, 144:32-40.
35. Elias C.B., Zeiser A., Bedard C., Kamen A.A. Enhanced growth of Sf-9 cells to a maximum density of 5.2 x 107 cells per ml, and production of beta-galactosidase at high cell density by fed batch culture. Biotechnol. Bioeng. 2000, 68:381-388.
36. Erles K., Sebokova P., Schlehofer J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 1999, 59:406-411.
37. Fan P.D., Dong J.Y. Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum. Gene Ther. 1997, 8:87-98.
38. Farson D., Harding T.C., Tao L., Liu J., Powell S., Vimal V., Yendluri S., Koprivnikar K., Ho K., Twitty C., Husak P., Lin A., Snyder R.O., Donahue B.A. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene Med. 2004, 6:1369-1381.
39. Feng L., Guo M., Zhang S., Chu J., Zhuang Y., Zhang S. Optimization of transfection mediated by calcium phosphate for plasmid rAAV-LacZ (recombinant adeno-associated virus-beta-galactosidase reporter gene) production in suspension-cultured HEK-293 (human embryonic kidney 293) cells. Biotechnol. Appl. Biochem. 2007, 46:127-135.
40. Flotte T.R., Barraza-Ortiz X., Solow R., Afione S.A., Carter B.J., Guggino W.B. An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther. 1995, 2:29-37.
41. Galibert, L., Rivière, C., Cohen, D., van Oers, M., Merten, O.-W., 2010. Baculovirus deleted for chitinase, cathepsin and p10 genes improves purified rAAV8 quality. Presented at the Advanced Symposium and EMBO Practical Course on Viral Vectors in Gene Therapy - Applications & Novel Production Methods in Kuopio/SF, 26 August-4 September.
42. Gao G.P., Qu G., Faust L.Z., Engdahl R.K., Xiao W., Hughes J.V., Zoltick P.W., Wilson J.M. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum. Gene Ther. 1998, 9:2353-2362.
43. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 2002, 99:11854-11859.
44. Gao G.P., Lu F., Sanmiguel J.C., Tran P.T., Abbas Z., Lynd K.S., Marsh J., Spinner N.B., Wilson J.M. Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther. 2002, 5:644-649.
45. Gao G., Vandenberghe L.H., Alvira M.R., Lu Y., Calcedo R., Zhou X., Wilson J.M. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 2004, 78:6381-6388.
46. Gao G., Vandenberghe L.H., Wilson J.M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 2005, 5:285-297.
47. Girod A., Wobus C.E., Zadori Z., Ried M., Leike K., Tijssen P., Kleinschmidt J.A., Hallek M. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 2002, 83:973-978.
48. Goyenvalle A., Vulin A., Fougerousse F., Leturcq F., Kaplan J.C., Garcia L., Danos O. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004, 306(5702):1796-1799.
49. Grimm D., Kay M.A. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 2003, 3:281-304.
50. Grimm D., Kern A., Pawlita M., Ferrari F., Samulski R., Kleinschmidt J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 1999, 6:1322-1330.
51. Grimm D., Kern A., Rittner K., Kleinschmidt J.A. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 1998, 9:2745-2760.
52. Grimm D., Lee J.S., Wang L., Desai T., Akache B., Storm T.A., Kay M.A. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 2008, 82:5887-5911.
53. Harper S.Q., Hauser M.A., DelloRusso C., Duan D., Crawford R.W., Phelps S.F., Harper H.A., Robinson A.S., Engelhardt J.F., Brooks S.V., Chamberlain J.S. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 2002, 8(3):253-261.
54. Hermens, W., 2008. A modular and disposable manufacturing platform for adeno-associated viral (AAV) vectors. Presented at the ASGT 11th annual meeting, Boston/USA, 28 May/1 June, 2008.
55. High K.A. Clinical gene transfer studies for hemophilia B. Semin. Thromb. Hemost. 2004, 30:257-267.
56. Hildinger M., Baldi L., Stettler M., Wurm F.M. High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. Biotechnol. Lett. 2007, 29:1713-1721.
57. Hitchman R.B., Possee R.D., King L.A. Baculovirus expression systems for recombinant protein production in insect cells. Recent Pat. Biotechnol. 2009, 3:46-54.
58. Hitchman R.B., Possee R.D., Crombie A.T., Chambers A., Ho K., Siaterli E., Lissina O., Sternard H., Novy R., Loomis K., Bird L.E., Owens R.J., King L.A. Genetic modification of a baculovirus vector for increased expression in insect cells. Cell Biol. Toxicol. 2010, 26:57-68.
59. Horer M., Weger S., Butz K., Hoppe-Seyler F., Geisen C., Kleinschmidt J.A. Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J. Virol. 1995, 69:5485-5496.
60. Hu Y.C., Bentley W.E. A kinetic and statistical-thermodynamic model for baculovirus infection and virus-like particle assembly in suspended insect cells. Chem. Eng. Sci. 2000, 55:3991-4008.
61. Ikemoto M., Fukada S., Uezumi A., Masuda S., Miyoshi H., Yamamoto H., Wada M.R., Masubuchi N., Miyagoe-Suzuki Y., Takeda S. Autologous transplantation of SM/C-2.6(+) satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. Mol. Ther. 2007, 15:2178-2185.
62. Ikonomou L., Schneider Y.J., Agathos S.N. Insect cell culture for industrial production of recombinant proteins. Appl. Microbiol. Biotechnol. 2003, 62:1-20.
63. Jarvis D.L. Baculovirus-insect cell expression systems. Methods Enzymol. 2009, 463:191-222.
64. Kaba S.A., Salcedo A.M., Wafula P.O., Vlak J.M., van Oers M.M. Development of a chitinase and v-cathepsin negative bacmid for improved integrity of secreted recombinant proteins. J. Virol. Methods 2004, 122:113-118.
65. Kajigaya S., Fujii H., Field A., Anderson S., Rosenfeld S., Anderson L.J., Shimada T., Young N.S. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc. Natl. Acad. Sci. USA. 1991, 88:4646-4650.
66. Kang W., Wang L., Harrell H., Liu J., Thomas D.L., Mayfield T.L., Scotti M.M., Ye G.J., Veres G., Knop D.R. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther. 2009, 16:229-239.
67. King J.A., Dubielzig R., Grimm D., Kleinschmidt J.A. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. Embo J. 2001, 20:3282-3291.
68. Kirnbauer R., Taub J., Greenstone H., Roden R., Dürst M., Gissmann L., Lowy D.R., Schiller J.T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 1993, 67:6929-6936.
69. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., Kunkel L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987, 50:509-517.
70. Kohlbrenner E., Aslanidi G., Nash K., Shklyaev S., Campbell-Thompson M., Byrne B.J., Snyder R.O., Muzyczka N., Warrington K.H.Jr., Zolotukhin S. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 2005, 12:1217-1225.
71. Kool M., Voncken J.W., van Lier F.L., Tramper J., Vlak J.M. Detection and analysis of Autographa californica nuclear polyhedrosis virus mutants with defective interfering properties. Virology 1991, 183:739-746.
72. Kotin, R.M., 2010. AAV vector production using baculovirus expression system -Comparison with traditional methods. Presented at the Advanced Symposium and EMBO Practical Course on Viral vectors in Gene Therapy - Applications & Novel Production Methods in Kuopio/SF, 26 August-4 September, 2010.
73. Kotin R.M., Siniscalco M., Samulski R.J., Zhu X.D., Hunter L., Laughlin C.A., McLaughlin S., Muzyczka N., Rocchi M., Berns K.I. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 1990, 87:2211-2215.
74. Lee H.Y., Krell P.J. Generation and analysis of defective genomes of Autographa californica nuclear polyhedrosis virus. J. Virol. 1992, 66:4339-4347.
75. Li J., Samulski R.J., Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol; 1997, 71:5236-5243.
76. Li W., Asokan A., Wu Z., Van Dyke T., DiPrimio N., Johnson J.S., Govindaswamy L., Agbandje-McKenna M., Leichtle S., Redmond D.E., McCown T.J., Petermann K.B., Sharpless N.E., Samulski R.J. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 2008, 16:1252-1260.
77. Liu X.L., Clark K.R., Johnson P.R. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 1999, 6:293-299.
78. Liu X., Voulgaropoulou F., Chen R., Johnson P.R., Clark K.R. Selective rep-cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther. 2000, 2:394-403.
79. Maguire A.M., High K.A., Auricchio A., Wright J.F., Pierce E.A., Testa F., Mingozzi F., Bennicelli J.L., Ying G.S., Rossi S., Fulton A., Marshall K.A., Banfi S., Chung D.C., Morgan J.I., Hauck B., Zelenaia O., Zhu X., Raffini L., Coppieters F., De Baere E., Shindler K.S., Volpe N.J., Surace E.M., Acerra C., Lyubarsky A., Redmond T.M., Stone E., Sun J., McDonnell J.W., Leroy B.P., Simonelli F., Bennett J. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374:1597-1605.
80. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., Ozelo M.C., Hoots K., Blatt P., Konkle B., Dake M., Kaye R., Razavi M., Zajko A., Zehnder J., Rustagi P.K., Nakai H., Chew A., Leonard D., Wright J.F., Lessard R.R., Sommer J.M., Tigges M., Sabatino D., Luk A., Jiang H., Mingozzi F., Couto L., Ertl H.C., High K.A., Kay M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12:342-347.
81. Mansilla-Soto J., Yoon-Robarts M., Rice W.J., Arya S., Escalante C.R., Linden R.M. DNA structure modulates the oligomerization properties of the AAV initiator protein Rep68. PLoS Pathog. 2009, 5:e1000513.
82. Maranga L., Brazao T.F., Carrondo M.J. Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system. Biotechnol. Bioeng. 2003, 84:245-253.
83. Marek M., van Oers M.M., Devaraj F.F., Vlak J.M., Merten O.-W. Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol. Bioeng. 2011, 10.1002/bit.23028.
84. Mathews L.C., Gray J.T., Gallagher M.R., Snyder R.O. Recombinant adeno-associated viral vector production using stable packaging and producer cell lines. Methods Enzymol. 2002, 346:393-413.
85. Matsushita T., Elliger S., Elliger C., Podsakoff G., Villarreal L., Kurtzman G.J., Iwaki Y., Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998, 5:938-945.
86. Matsushita T., Okada T., Inaba T., Mizukami H., Ozawa K., Colosi P. The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production. J. Gen. Virol. 2004, 85:2209-2214.
87. McPherson C.E. Development of a novel recombinant influenza vaccine in insect cells. Biologicals 2008, 36:350-353.
88. McPherson R.A., Rosenthal L.J., Rose J.A. Human cytomegalovirus completely helps adeno-associated virus replication. Virology 1985, 147:217-222.
89. Mellado M.C., Peixoto C., Cruz P.E., Carrondo M.J., Alves P.M. Purification of recombinant rotavirus VP7 glycoprotein for the study of in vitro rotavirus-like particles assembly. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 874:89-94.
90. Mena, J.A., Aucoin, M.G., Chahal, P.S., Kamen, A.A., 2008. Combining asynchronous and synchronous infections in a multi-baculovirus system to improve the production of adeno-associated vectors. Poster Presented at the 4th Canadian Gene Therapy and Vaccines Symposium, Montreal, 26-27 May, 2008.
91. Mena J.A., Aucoin M.G., Montes J., Chahal P.S., Kamen A.A. Improving adeno-associated vactor yield in high density insect cell cultures. J. Gene Med. 2010, 12:157-167.
92. Mena J.A., Ramirez O.T., Palomares L.A. Population kinetics during simultaneous infection of insect cells with two different recombinant baculoviruses for the production of rotavirus-like particles. BMC Biotechnol. 2007, 7:39.
93. Merten, O.-W., 2009. Large Scale Production of AAV - improvements. Presented at the 17th Annual Congress of the ESGCT Meeting in Hannover/D, 20-25 November, 2009.
94. Merten O.-W., Gény-Fiamma C., Douar A.M. Current issues in adeno-associated viral vectors production. Gene Ther. 2005, 12(S1):S51-S61.
95. Monaco A.P., Bertelson C.J., Liechti-Gallati S., Moser H., Kunkel L.M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988, 2:90-95.
96. Monaco A.P., Neve R.L., Colletti-Feener C., Bertelson C.J., Kurnit D.M., Kunkel L.M. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986, 323:646-650.
97. Mori S., Wang L., Takeuchi T., Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004, 330:375-383.
98. Nakamura A., Takeda S. Exon-skipping therapy for Duchenne muscular dystrophy. Neuropathology 2009, 29:494-501.
99. Negrete A., Yang L.C., Mendez A.F., Levy J.R., Kotin R.M. Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J. Gene Med. 2007, 9:938-948.
100. Negroni E., Riederer I., Chaouch S., Belicchi M., Razini P., Di Santo J., Torrente Y., Butler-Browne G.S., Mouly V. In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study. Mol. Ther. 2009, 17:1771-1778.
101. Ohshima S., Shin J.H., Yuasa K., Nishiyama A., Kira J., Okada T., Takeda S. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol. Ther. 2009, 17:73-80.
102. Palfi S. Towards gene therapy for Parkinson's disease. Lancet Neurol. 2008, 7:375-376.
103. Palomares L.A., Lopez S., Ramirez O.T. Utilization of oxygen uptake rate to assess the role of glucose and glutamine in the metabolism of infected insect cell cultures. Biochem. Eng. J. 2004, 19:87-93.
104. Park J.Y., Lim B.P., Lee K., Kim Y.G., Jo E.C. Scalable production of adeno-associated virus type 2 vectors via suspension transfection. Biotechnol. Bioeng. 2006, 94:416-430.
105. Pereira D.J., McCarty D.M., Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J. Virol. 1997, 71:1079-1088.
106. Pijlman G.P., van Schijndel J.E., Vlak J.M. Spontaneous excision of BAC vector sequences from bacmid-derived baculovirus expression vectors upon passage in insect cells. J. Gen. Virol. 2003, 84:2669-2678.
107. Pijlman G.P., Vermeesch A.M., Vlak J.M. Cell line-specific accumulation of the baculovirus non-hr origin of DNA replication in infected insect cells. J. Invertebr. Pathol. 2003, 84:214-219.
108. Pijlman G.P., Dortmans J.C., Vermeesch A.M., Yang K., Martens D.E., Goldbach R.W., Vlak J.M. Pivotal role of the non-hr origin of DNA replication in the genesis of defective interfering baculoviruses. J. Virol. 2002, 76:5605-5611.
109. Qiao C., Li J., Skold A., Zhang X., Xiao X. Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J. Virol. 2002, 76:1904-1913.
110. Qiao C., Wang B., Zhu X., Li J., Xiao X. A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol. 2002, 76:13015-13027.
111. Qiu J., Pintel D.J. Alternative polyadenylation of adeno-associated virus type 5 RNA within an internal intron is governed by the distance between the promoter and the intron and is inhibited by U1 small nuclear RNP binding to the intervening donor. J. Biol. Chem. 2004, 279:14889-14898.
112. Qu G., McClelland A., Wright J.F. Scaling-up production of recombinant AAV vectors for clinical applications. Curr. Opin. Drug Discov. Devel. 2000, 3:750-755.
113. Rabinowitz J.E., Rolling F., Li C., Conrath H., Xiao W., Xiao X., Samulski R.J. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 2002, 76:791-801.
114. Rodino-Klapac L.R., Janssen P.M., Montgomery C.L., Coley B.D., Chicoine L.G., Clark K.R., Mendell J.R. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J. Transl. Med. 2007, 5:45.
115. Ruffing M., Zentgraf H., Kleinschmidt J.A. Assembly of virus like particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J. Virol. 1992, 66:6922-6930.
116. Rutledge E.A., Halbert C.L., Russell D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 1998, 72:309-319.
117. Salvetti A., Orève S., Chadeuf G., Favre D., Cherel Y., Champion-Arnaud P., David-Ameline J., Moullier P. Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 1998, 9:695-706.
118. Sampaolesi M., Blot S., D'Antona G., Granger N., Tonlorenzi R., Innocenzi A., Mognol P., Thibaud J.L., Galvez B.G., Barthélémy I., Perani L., Mantero S., Guttinger M., Pansarasa O., Rinaldi C., Cusella De Angelis M.G., Torrente Y., Bordignon C., Bottinelli R., Cossu G. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006, 444:574-579.
119. Samulski R.J., Berns K.I., Tan M., Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl. Acad. Sci. USA 1982, 79:2077-2081.
120. Samulski R.J., Chang L.S., Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 1987, 61:3096-3101.
121. Samulski R.J., Zhu X., Xiao X., Brook J.D., Housman D.E., Epstein N., Hunter L.A. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. Embo J. 1991, 10:3941-3950.
122. Schlehofer J.R., Ehrbar M., zur Hausen H. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. Virology 1986, 152:110-117.
123. Schmidt M., Voutetakis A., Afione S., Zheng C., Mandikian D., Chiorini J.A. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 2008, 82:1399-1406.
124. Shelling S.N., Smith M.G. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin gene. Gene Ther. 1994, 1:165-169.
125. Shi Y., Seto E., Chang L.-S., Shenk T. Transcriptional activation by YY1, a human GL1-Krüppel-related protein, and relief of repression by adenovirus EIA protein. Cell 1991, 67:377-388.
126. Simonelli F., Maguire A.M., Testa F., Pierce E.A., Mingozzi F., Bennicelli J.L., Rossi S., Marshall K., Banfi S., Surace E.M., Sun J., Redmond T.M., Zhu X., Shindler K.S., Ying G.S., Ziviello C., Acerra C., Wright J.F., McDonnell J.W., High K.A., Bennett J., Auricchio A. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 2010, 18:643-650.
127. Smith R.H., Levy J.R., Kotin R.M. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol. Ther. 2009, 17:1888-1896.
128. Sonntag F., Schmidt K., Keinschmidt J.A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 2010, 107:10220-10225.
129. Srivastava A., Lusby E.W., Berns K.I. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 1983, 45:555-564.
130. Taticek R.A., Shuler M.L. Effect of elevated oxygen and glutamine levels on foreign protein production at high cell densities using the insect cell-baculovirus expression system. Biotechnol. Bioeng. 1997, 54:142-152.
131. Thomas D.L., Wang L., Niamke J., Liu J., Kang W., Scotti M.M., Ye G.J., Veres G., Knop D.R. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum. Gene Ther. 2009, 20:861-870.
132. Thorne, B., 2003. Scaleable processes for rAAV manufacturing. WilBio Meeting on Viral Vectors & Vaccines - Process Development and Production Issues, Las Vegas, NE, 2003.
133. Tiga S.T., zu Altenschildesche G.M., Doerfler W. Autographa Californica nuclear polyhedrosis virus (AcNPV) FNA does not pesist in mass cultures of mammalian cells. Virology 1983, 125:107-117.
134. Timpe J., Bevington J., Casper J., Dignam J.D., Trempe J.P. Mechanisms of adeno-associated virus genome encapsidation. Curr. Gene Ther. 2005, 5:273-284.
135. Tobiasch E., Burguete T., Klein-Bauernschmitt P., Heilbronn R., Schlehofer J.R. Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. J. Virol. Methods 1998, 71:17-25.
136. Toublanc E., Benraiss A., Bonnin D., Blouin V., Brument N., Cartier N., Epstein A.L., Moullier P., Salvetti A. Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J. Gene Med. 2004, 6:555-564.
137. Tratschin J.D., Miller I.L., Carter B.J. Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J. Virol. 1984, 51:611-619.
138. Tratschin J.D., Miller I.L., Smith M.G., Carter B.J. Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol. Cell. Biol. 1985, 5:3251-3260.
139. Urabe M., Ding C., Kotin R.M. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 2002, 13:1935-1943.
140. Urabe, M., Ozawa, K., Haast, S., Hermens, W., 2006. Improved AAV Vectors Produced in Insect Cells. WO/2007/046703.
141. van Lier F.L., van der Meijs W.C., Grobben N.G., Olie R.A., Vlak J.M., Tramper J. Continuous beta-galactosidase production with a recombinant baculovirus insect-cell system in bioreactors. J. Biotechnol. 1992, 22:291-298.
142. van Oers M.M. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv. Virus Res. 2006, 68:193-253.
143. van Oers M.M. Opportunities and challenges for the baculovirus expression system. J. Invertebr. Pathol. 2011, 107:S3.
144. Vicente T., Peixoto C., Carrondo M., Alves P. Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Ther. 2009, 16:766-775.
145. Vicente T., Roldão A., Peixoto C., Carrondo M.J.T., Alves P.M. Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. 2011, 107:S42.
146. Virag T., Cecchini S., Kotin R.M. Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum. Gene Ther. 2009, 20:807-817.
147. Wang B., Li J., Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA 2000, 97:13714-13719.
148. Warrington K.H., Herzog R.W. Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet. 2006, 119:571-603.
149. Weindler F.W., Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J. Virol. 1991, 65:2476-2483.
150. Weitzman M.D., Kyostio S.R., Kotin R.M., Owens R.A. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc. Natl. Acad. Sci. USA 1994, 91:5808-5812.
151. Welch E.M., Barton E.R., Zhuo J., Tomizawa Y., Friesen W.J., Trifillis P., Paushkin S., Patel M., Trotta C.R., Hwang S., Wilde R.G., Karp G., Takasugi J., Chen G., Jones S., Ren H., Moon Y.C., Corson D., Turpoff A.A., Campbell J.A., Conn M.M., Khan A., Almstead N.G., Hedrick J., Mollin A., Risher N., Weetall M., Yeh S., Branstrom A.A., Colacino J.M., Babiak J., Ju W.D., Hirawat S., Northcutt V.J., Miller L.L., Spatrick P., He F., Kawana M., Feng H., Jacobson A., Peltz S.W., Sweeney H.L. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
152. Wickham T.J. Screening of insect cell lines for the production of recombinant protein and infectious virus in the baculovirus expression system. Biotechnol. Prog. 1992, 8:391-396.
153. Wistuba A., Kern A., Weger S., Grimm D., Kleinschmidt J.A. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 1997, 71:1341-1352.
154. Wu Z., Asokan A., Samulski R.J. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol. Ther. 2006, 14:316.
155. Wustner J.T., Arnold S., Lock M., Richardson J.C., Himes V.B., Kurtzman G., Peluso R.W. Production of recombinant adeno-associated type 5 (rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. Mol. Ther. 2002, 6:510-518.
156. Xiao X., Li J., Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 1998, 72:2224-2323.
157. Xiao W., Chirmule N., Berta S.C., McCullough B., Gao G., Wilson J.M. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 1999, 73:3994-4003.
158. Yoshimura M., Sakamoto M., Ikemoto M., Mochizuki Y., Yuasa K., Miyagoe-Suzuki Y., Takeda S. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol. Ther. 2004, 10:821-828.
159. Yuan Z., Qiao C., Hu P., Li J., Xiao X. A versatile AAV producer cell line method for scalable vector production of different serotypes. Hum. Gene Ther. 2010, 10.1089/hum.2010.241.
160. Zhang Y.H., Merchuk J.C. A mathematical model of baculovirus infection on insect cells at low multiplicity of infection. Acta Biochim. Biophys. Sin. 2004, 36:729-740.